File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival

TitleProtein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival
Authors
Issue Date2008
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2008, v. 122 n. 11, p. 2554-2561 How to Cite?
AbstractAIB1, a candidate oncogene in human breast cancer, is frequently amplified and overexpressed in several types of human cancers, but the status of AIB1 amplification and expression in urothelial carcinoma of the bladder (UC) and its clinical/prognostic significance is unclear. In our study, the methods of immunohistochemistry and fluorescence in situ hybridization were utilized to examine protein expression and amplification of AIB1 in 163 primary UCs and in 30 samples of normal bladder mucosa. Overexpression of AIB1 and amplification of AIB1 was found in 32.5 and 7.0% of UCs, respectively. In univariate survival analysis of the UC cohorts, a highly significant association of overexpression of AIB1 with shortened patient survival (mean: 45.6 months vs. 59.0 months, p < 0.001, log rank test) was demonstrated. In different subsets of UC patients, overexpression of AIB1 was also a prognostic indicator in grade 1 (p = 0.007), grade 2 (p = 0.010) and grade 3 (p = 0.015) tumor patients, and in pTa (p = 0.025), pT2-4 (p = 0.004), pN0 (p < 0.001) and pT2-4/pN0 (p = 0.040) tumor patients. Importantly, AIB1 expression (p < 0.001) together with pT and pN status (p < 0.05) provided significant independent prognostic parameters in multivariate analysis. In addition, a significant correlation (p < 0.05) of overexpression of AIB1 with an increased UC labeling index of Ki-67 (a cell proliferation marker) was observed in these UCs. Thus, these findings provide evidence that an overexpression of AIB1, as detected by immunohistochemistry, is an independent molecular marker for poor prognosis (shortened survival time) of patients with UC. © 2008 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/150817
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.657
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLuo, JHen_US
dc.contributor.authorXie, Den_US
dc.contributor.authorLiu, MZen_US
dc.contributor.authorChen, Wen_US
dc.contributor.authorLiu, YDen_US
dc.contributor.authorWu, GQen_US
dc.contributor.authorKung, HFen_US
dc.contributor.authorZeng, YXen_US
dc.contributor.authorGuan, XYen_US
dc.date.accessioned2012-06-26T06:11:13Z-
dc.date.available2012-06-26T06:11:13Z-
dc.date.issued2008en_US
dc.identifier.citationInternational Journal Of Cancer, 2008, v. 122 n. 11, p. 2554-2561en_US
dc.identifier.issn0020-7136en_US
dc.identifier.urihttp://hdl.handle.net/10722/150817-
dc.description.abstractAIB1, a candidate oncogene in human breast cancer, is frequently amplified and overexpressed in several types of human cancers, but the status of AIB1 amplification and expression in urothelial carcinoma of the bladder (UC) and its clinical/prognostic significance is unclear. In our study, the methods of immunohistochemistry and fluorescence in situ hybridization were utilized to examine protein expression and amplification of AIB1 in 163 primary UCs and in 30 samples of normal bladder mucosa. Overexpression of AIB1 and amplification of AIB1 was found in 32.5 and 7.0% of UCs, respectively. In univariate survival analysis of the UC cohorts, a highly significant association of overexpression of AIB1 with shortened patient survival (mean: 45.6 months vs. 59.0 months, p < 0.001, log rank test) was demonstrated. In different subsets of UC patients, overexpression of AIB1 was also a prognostic indicator in grade 1 (p = 0.007), grade 2 (p = 0.010) and grade 3 (p = 0.015) tumor patients, and in pTa (p = 0.025), pT2-4 (p = 0.004), pN0 (p < 0.001) and pT2-4/pN0 (p = 0.040) tumor patients. Importantly, AIB1 expression (p < 0.001) together with pT and pN status (p < 0.05) provided significant independent prognostic parameters in multivariate analysis. In addition, a significant correlation (p < 0.05) of overexpression of AIB1 with an increased UC labeling index of Ki-67 (a cell proliferation marker) was observed in these UCs. Thus, these findings provide evidence that an overexpression of AIB1, as detected by immunohistochemistry, is an independent molecular marker for poor prognosis (shortened survival time) of patients with UC. © 2008 Wiley-Liss, Inc.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_US
dc.relation.ispartofInternational Journal of Canceren_US
dc.subject.meshAgeden_US
dc.subject.meshCarcinoma - Chemistry - Mortality - Pathologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshGene Expression Regulation, Neoplasticen_US
dc.subject.meshHistone Acetyltransferases - Analysisen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshIn Situ Hybridization, Fluorescenceen_US
dc.subject.meshKaplan-Meier Estimateen_US
dc.subject.meshKi-67 Antigen - Analysisen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMultivariate Analysisen_US
dc.subject.meshNuclear Receptor Coactivator 3en_US
dc.subject.meshPredictive Value Of Testsen_US
dc.subject.meshPrognosisen_US
dc.subject.meshProportional Hazards Modelsen_US
dc.subject.meshTrans-Activators - Analysisen_US
dc.subject.meshTumor Markers, Biological - Analysisen_US
dc.subject.meshUp-Regulationen_US
dc.subject.meshUrinary Bladder Neoplasms - Chemistry - Mortality - Pathologyen_US
dc.subject.meshUrothelium - Chemistry - Pathologyen_US
dc.titleProtein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survivalen_US
dc.typeArticleen_US
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_US
dc.identifier.authorityGuan, XY=rp00454en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/ijc.23399en_US
dc.identifier.pmid18246597-
dc.identifier.scopuseid_2-s2.0-42549087289en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-42549087289&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume122en_US
dc.identifier.issue11en_US
dc.identifier.spage2554en_US
dc.identifier.epage2561en_US
dc.identifier.isiWOS:000255466300019-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLuo, JH=7404183419en_US
dc.identifier.scopusauthoridXie, D=35070710200en_US
dc.identifier.scopusauthoridLiu, MZ=35285929300en_US
dc.identifier.scopusauthoridChen, W=16033282000en_US
dc.identifier.scopusauthoridLiu, YD=26662407500en_US
dc.identifier.scopusauthoridWu, GQ=24340411600en_US
dc.identifier.scopusauthoridKung, HF=7402514190en_US
dc.identifier.scopusauthoridZeng, YX=7402981579en_US
dc.identifier.scopusauthoridGuan, XY=7201463221en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats